Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

JP Morgan's Tessa Romero raised their price target on Acadia Pharmaceuticals (NASDAQ: ACAD) by 9.7% from $31 to $34 on 2026/03/04. The analyst maintained their Strong Buy rating on the stock.

Acadia Pharmaceuticals reported its Q4 and FY 2025 earnings.

Following an assessment of the print, Romero said they revised their model and hiked their price target.

According to the analyst, Acadia Pharmaceuticals is well-positioned to continue commercial and pipeline growth, which bodes well for stock price upside.

Earnings Report

Acadia Pharmaceuticals reported:

For Q4 2025:

• EPS of $0.16, which beat the Zacks Consensus Estimate of $0.12 but missed, by 5.9%, Q4 2024’s $0.17.
• Revenue of $283.99M, which missed the Zacks Consensus Estimate by 2.94% but beat, by 9%, Q4 2024’s $259.6M.

For FY 2025:

• GAAP EPS of $2.30, up 69.12% Y/Y.
• Revenue of $1.07B, up 12% Y/Y.

For FY 2026, management guided:

• Revenue of $1.22B to $1.28B.

CEO Catherine Owen Adams commented: “Acadia closed 2025 with another strong quarter, capping a milestone year in which we surpassed $1B in annual revenue for the first time.

“NUPLAZID had another strong quarter driven by underlying volume growth, reflecting continued momentum in the business. 

“In Q4, we received our first Inflation Reduction Act invoices for NUPLAZID inflation cap rebates, which resulted in NUPLAZID delivering GAAP net product sales of $174M and non-GAAP adjusted net product sales of $189M. 

“DAYBUE generated $110M in Q4 net product sales, driven by expanding reach in the community and continued contribution from named patient supply programs outside the U.S. 

“We are seeing growing interest in our new DAYBUE STIX powder formulation as we prepare for a full launch in early Q2 of this year. 

“We continue to advance a deep and differentiated R&D pipeline, anchored by remlifanserin, with the Phase 2 RADIANT study in Alzheimer’s disease psychosis serving as an important upcoming potential catalyst with top‑line results expected between 2026/08 and 2026/10.”